NIAMI: Nitroprusside infusion prior to primary angioplasty

The phenomenon of reperfusion injury is responsible for 50 % of the final infarct size. Several pharmacological and non-pharmacological agents administered before or during the ischemic period could significantly reduce infarct size in experimental studies in humans, but the results were inconsistent.

This study tested the hypothesis that intravenous nitroprusside infusion immediately before the opening of the infarct-related artery could reduce reperfusion injury. Patients were included within 12 hours of onset of symptoms with TIMI 0-1 flow in the culprit artery. The primary end point was the infarct size measured by MRI. 280 patients were randomized (146 nitroprusside and 134 placebo) could not demonstrate significant differences between both groups after a week and at 6 months.

Conclusion:

The intravenous infusion of sodium nitroprusside 5 minutes before primary angioplasty did not reduce infarct size.

2_nishat_siddiqi
Nishat Siddiqi
2013-11-17

Original title: Nitrites in Acute Myocardial Infarction.

More articles by this author

Mild hypothermia in pre-hospital phase after cardiac arrest

Hypothermia in the hospital phase at 32-34 ° C improves neurological outcome in patients resuscitated after ventricular fibrillation out of the hospital environment. In...

TTM: Hypothermia after cardiac arrest does not offer benefits

Previous studies evaluated therapeutic hypothermia (32 ° C to 34 ° C for 12-24 hours) in patients who remain unconscious after resuscitation from cardiac...

CATIS: Immediate reduction in blood pressure demonstrated no benefit in acute stroke

It is shown that hypertension is associated with the occurrence of stroke but immediate treatment for an acute stroke itself is unclear. This study...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....